Cita APA

Halatsch, M., Kast, R. E., Dwucet, A., Hlavac, M., Heiland, T., Westhoff, M., . . . Karpel‐Massler, G. (2019). Bcl‐2/Bcl‐xL inhibition predominantly synergistically enhances the anti‐neoplastic activity of a low‐dose CUSP9 repurposed drug regime against glioblastoma. Br J Pharmacol.

Chicago Style Citation

Halatsch, Marc‐Eric, et al. "Bcl‐2/Bcl‐xL Inhibition Predominantly Synergistically Enhances the Anti‐neoplastic Activity of a Low‐dose CUSP9 Repurposed Drug Regime against Glioblastoma." Br J Pharmacol 2019.

Cita MLA

Halatsch, Marc‐Eric, et al. "Bcl‐2/Bcl‐xL Inhibition Predominantly Synergistically Enhances the Anti‐neoplastic Activity of a Low‐dose CUSP9 Repurposed Drug Regime against Glioblastoma." Br J Pharmacol 2019.